论文部分内容阅读
目的探讨血浆纤维蛋白原(FIB)水平在卵巢肿瘤临床诊断中的价值。方法选择2012年3月至2013年9月间诊治的120例原发上皮性卵巢癌患者为观察组,100例卵巢良性肿瘤患者为对照组。分析两组患者的血浆FIB水平,以及不同分期的原发上皮性卵巢癌患者血浆FIB水平、和不同临床病理因素的原发性卵巢上皮癌患者血浆FIB水平。结果观察组患者血浆FIB水平增高的发生率为40.0%,对照组为7.0%,差异有统计学意义(2=7.81,P=0.028)。不同分期的原发上皮性卵巢癌患者血浆FIB水平之间差异有统计学意义(P<0.05)。随着原发上皮性卵巢癌分期的升高,血浆FIB水平增高的发生率也增加(2=6.98,P=0.041)。早期(Ⅰ、Ⅱ期)和晚期(Ⅲ、Ⅳ期)原发上皮性卵巢癌患者的血浆FIB水平之间差异有统计学意义(t=7.21,P=0.036)。不同组织学分级和不同腹水量患者的血浆FIB水平增高的差异无统计学意义(P>0.05),但在术后残留病灶>2 cm的患者中,血浆FIB增高的发生率高于≤2 cm者,差异有统计学意义(2=7.60,P=0.031)。结论血浆FIB水平对于原发上皮性卵巢癌患者的病情诊断和评估有一定的价值。
Objective To investigate the value of plasma fibrinogen (FIB) in the clinical diagnosis of ovarian tumors. Methods 120 patients with primary epithelial ovarian cancer diagnosed and treated between March 2012 and September 2013 were selected as observation group and 100 patients with benign ovarian tumor as control group. The level of plasma FIB in patients with primary epithelial ovarian cancer at different stages and plasma FIB levels in patients with primary epithelial ovarian cancer with different clinical and pathological factors were analyzed. Results The incidence of plasma FIB increased 40.0% in the observation group and 7.0% in the control group (2 = 7.81, P = 0.028). There were significant differences in plasma FIB levels in patients with primary epithelial ovarian cancer at different stages (P <0.05). As the staging of primary epithelial ovarian cancer increased, the incidence of increased plasma FIB levels also increased ( 2 = 6.98, P = 0.041). There was significant difference in plasma FIB levels between patients with primary epithelial ovarian cancer (stage Ⅰ, Ⅱ) and advanced (stage Ⅲ, Ⅳ) (t = 7.21, P = 0.036). There was no significant difference in plasma FIB levels between patients with different histological grades and different amounts of ascites (P> 0.05). However, the incidence of plasma FIB increased more than 2 cm in patients with postoperative residual lesions> 2 cm The difference was statistically significant (2 = 7.60, P = 0.031). Conclusions The level of plasma FIB has some value in the diagnosis and evaluation of the patients with primary epithelial ovarian cancer.